Summary
The provided claims largely align with FDA labeling language only for abuse/misuse/addiction, but multiple other claims are not supported and/or are inconsistent with the supplied Xelstrym prescribing information context (which lists dextroamphetamine, not filgrastim/patch use for neutropenia).
Category Scores
Accurate Statements
Xelstrym has potential for abuse/misuse that can lead to substance use disorder, including addiction.
Supported by Label Section 5.1 (high potential for abuse/misuse leading to substance use disorder, including addiction) and Section 9.2 (same linkage).
Unsupported Statements
Xelstrym (filgrastim-aafi) is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF).
The supplied labeling excerpts indicate XELSTRYM contains dextroamphetamine (Sections 9.1/9.2 context); filgrastim-aafi/GM-CSF identity is not supported by the provided label information.
Xelstrym is used to support neutrophil count in patients with chronic neutropenia.
The supplied label excerpt includes an indication for ADHD, not chronic neutropenia/neutrophil count support.
Xelstrym reduces the incidence of infection, fever, and neutropenia caused by chemotherapy.
No such efficacy claim appears in the provided labeling excerpts; only ADHD indication is shown.
Xelstrym is administered via a patch that releases a controlled dose of filgrastim over a period of days.
The supplied label excerpts do not describe filgrastim dosing by a patch; they are focused on abuse/misuse/addiction and controlled substance status for dextroamphetamine.
An estimated price range for Xelstrym patches is between $20,000 and $50,000 per year depending on dose and patient's weight.
No pricing information is present in the provided FDA label excerpts.
Xelstrym coverage varies depending on the insurance provider and patient's plan.
No payer/coverage policy statements are present in the provided FDA label excerpts.
Some insurance providers cover Xelstrym.
No coverage statements are present in the provided FDA label excerpts.
Some insurance providers may not cover Xelstrym.
No coverage statements are present in the provided FDA label excerpts.
Contradictions
High
AI Statement
Xelstrym (filgrastim-aafi) is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF).
Label Reference
Label indicates XELSTRYM contains dextroamphetamine (Section 9.1 — Controlled Substance).
High
AI Statement
Xelstrym is used to support neutrophil count in patients with chronic neutropenia.
Label Reference
Label Section 1 indicates XELSTRYM is indicated for treatment of ADHD in adults and pediatric patients 6 years and older.
High
AI Statement
Xelstrym reduces the incidence of infection, fever, and neutropenia caused by chemotherapy.
Label Reference
Provided label excerpt does not include this indication/efficacy; Section 1 indicates ADHD only.
High
AI Statement
Xelstrym is administered via a patch that releases a controlled dose of filgrastim over a period of days.
Label Reference
Provided label excerpts describe dextroamphetamine controlled substance abuse/misuse context, not filgrastim administration.
Important Omissions
If the question is about abuse/misuse/addiction, the labeling also recommends specific actions such as assessing patient risk before prescribing, educating patients/families, advising proper disposal, safe/locked storage, not giving to others, and frequent monitoring for signs/symptoms. None of these operational recommendations were included in the provided set of claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Only one claim (abuse/misuse leading to substance use disorder/addiction) is directly supported by the provided label excerpts; other claims are unsupported and include material identity/indication contradictions, which could mislead interpretation, but they are not directly prescribing instructions in the provided claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Mostly Aligned
Primary Issue
Multiple claims incorrectly describe Xelstrym as filgrastim-aafi/GM-CSF, assign an indication unrelated to the label provided (chronic neutropenia/chemotherapy-related neutropenia), and describe a filgrastim patch/dosing not supported by the provided labeling excerpts.
Suggested Improvement
Limit claims to those supported by the supplied labeling excerpts (e.g., abuse/misuse/addiction potential per Sections 5.1 and 9.2) and remove or replace unsupported/contradictory descriptions of active ingredient, indication, and administration.